Obstructive sleep apnea occurs in 2-4% of middle age adults and results in significant morbidity and mortality. The first line therapy is provision of continuous positive airway pressure (CPAP) via a nasal mask chronically. Nasal resistance related to nasal turbinate enlargement may compromise CPAP treatment. This randomized double-blind sham-placebo-controlled trial tests the hypothesis that nasal turbinate reduction improves the nasal passage, CPAP use, and sleep apnea quality of life in newly diagnosed sleep apnea patients who are recommended CPAP therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Nasal minimum cross-sectional area (measured objectively with acoustic rhinometry)
Timeframe: Primary outcome at 3 months, secondary outcomes at 6 and 12 months
CPAP use (measured objectively as pressure-on use)
Timeframe: Primary outcome at 3 months, secondary outcomes at 6 and 12 months
Sleep Apnea Quality of Life Index (change measured with Then Test technique)
Timeframe: Primary outcome at 3 months, secondary outcomes at 6 and 12 months